NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

$150,000 Initially, for manual production and for the second year can be either 50,000 or 100,000 additional, depending upon dose production. For 1 or 2 additional doses it is 50,000 and for 3 or more additional doses, it is 100,000. Total, $250,000. And depending on the number of doses produced, and assuming biannual shots, that can potentially last more than the second year. I would presume that they could produce no more doses, and they could produce another 6 doses. So doctors will want to get as much tumor as possible to save their patients costs.

$250,000. That puts them around $10, 416.66 per month. That is much cheaper than, for instance, Optune, at $21,000 per month. Other immunotherapies can also be more expensive per month. I did not include VAT for Optune. 21,000 x 12 = $252,000 + $50,400 for VAT = 302,400 per year out of pocket.

Looks like VAT (tax) is around $30,000, or 20%. I presume that is when it is out of pocket only.

Assuming DCVax-L extends survival and costs less per month by. substantial amount, it would be hard to believe a regulator would not think this is an advance over current other treatments.